[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK0755249T3 - Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom - Google Patents

Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom

Info

Publication number
DK0755249T3
DK0755249T3 DK95915254T DK95915254T DK0755249T3 DK 0755249 T3 DK0755249 T3 DK 0755249T3 DK 95915254 T DK95915254 T DK 95915254T DK 95915254 T DK95915254 T DK 95915254T DK 0755249 T3 DK0755249 T3 DK 0755249T3
Authority
DK
Denmark
Prior art keywords
maillard reaction
reaction inhibitor
based disease
treat amyloidosis
amyloidosis
Prior art date
Application number
DK95915254T
Other languages
Danish (da)
English (en)
Inventor
Camilo Colaco
Bruce Joseph Roser
Original Assignee
Elan Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10753465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0755249(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Drug Delivery Ltd filed Critical Elan Drug Delivery Ltd
Application granted granted Critical
Publication of DK0755249T3 publication Critical patent/DK0755249T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK95915254T 1994-04-13 1995-04-13 Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom DK0755249T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9407305A GB2288732B (en) 1994-04-13 1994-04-13 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
DK0755249T3 true DK0755249T3 (da) 2004-07-26

Family

ID=10753465

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95915254T DK0755249T3 (da) 1994-04-13 1995-04-13 Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom

Country Status (11)

Country Link
US (2) US5891873A (de)
EP (1) EP0755249B1 (de)
JP (1) JPH09512005A (de)
AT (1) ATE262895T1 (de)
AU (1) AU2219795A (de)
DE (1) DE69532804T2 (de)
DK (1) DK0755249T3 (de)
ES (1) ES2216012T3 (de)
GB (1) GB2288732B (de)
PT (1) PT755249E (de)
WO (1) WO1995028151A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
ES2179831T3 (es) * 1992-09-29 2003-02-01 Inhale Therapeutic Syst Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
ES2316917T3 (es) * 1994-03-07 2009-04-16 Nektar Therapeutics Metodos y composiciones para suministro pulmonar de insulina.
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions
MX9605717A (es) * 1994-05-18 1998-05-31 Inhale Therapeutic Syst Metodos y composiciones para la formulacion de polvo seco de interferones.
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5780513A (en) * 1996-08-22 1998-07-14 Washington University Method of inhibiting the release of bioactive IL-1
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
JPH1143432A (ja) * 1997-07-25 1999-02-16 Biremo Sci:Kk 脳の老化抑制及び治療剤
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
EP1053749A4 (de) * 1998-02-03 2003-01-15 Senju Pharma Co Vorbeuge- und heilmittel für neurodegenerative erkrankungen
GB9916316D0 (en) 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
JP2003531570A (ja) * 1999-07-27 2003-10-28 アブジェニックス インク. 神経障害に関連したポリペプチド蓄積を阻害する方法および組成物
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU6124601A (en) 2000-05-10 2001-11-20 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
AU2001280934A1 (en) * 2000-07-28 2002-02-13 Alliance Pharmaceutical Corp. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
CA2607663C (en) * 2005-05-19 2014-08-12 Amgen Inc. Compositions and methods for increasing the stability of antibodies
EP1893576A4 (de) * 2005-05-27 2010-03-17 Univ Kingston Behandlung von proteinfaltungsstörungen
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
CL2007002880A1 (es) * 2006-10-06 2008-05-09 Amgen Inc Formulacion estable que comprende un tampon de acido acetico, un tampon de acido glutamico o un tampon de acido succinico con un ph de 4,5 a 7, por lo menos un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor d
US7705132B2 (en) * 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
WO2018225623A1 (ja) 2017-06-07 2018-12-13 天野エンザイム株式会社 ラクターゼ原末及びラクターゼ製剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325936A3 (de) * 1988-01-16 1990-01-17 Ono Pharmaceutical Co., Ltd. Aminoguanidin-Derivate und für die Maillardreaktion inhibitorische Substanzen, die sie als aktive Inhaltsstoffe enthalten
JPH03161441A (ja) * 1989-11-20 1991-07-11 Senjiyu Seiyaku Kk メイラード反応阻害剤
JP2854631B2 (ja) * 1989-11-21 1999-02-03 千寿製薬株式会社 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤
IL110622A (en) * 1989-11-28 1995-03-30 Syntex Inc N-cyclic carboxamides are converted by cyclic amines
EP0474874B1 (de) * 1990-02-19 1995-10-18 Senju Pharmaceutical Co., Ltd. Zusammensetzungen von Maillard-Reaktion inhibitoren
PT96930B (pt) * 1990-03-02 1998-06-30 Univ Oregon Metodo para a utilizacao de guanidinas tri- e tetra-substituidas como antagonistas de amino-acidos excitadores
US5112596A (en) * 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
PT100115B (pt) * 1991-02-08 1999-06-30 Cambridge Neuroscience Inc Guanidinas substituidas e seus derivados uteis como moduladores de libertacao de neurotransmissores e ensaios de rastreio para de bloqueadores de libertacao de neurotransmissores
TW221689B (de) * 1991-08-27 1994-03-11 Otsuka Pharma Co Ltd
US5453514A (en) * 1992-12-25 1995-09-26 Yamanouchi Pharmaceutical Co., Ltd. Pyrazole derivatives and compositions and methods of use as maillard reaction inhibitors
US5935927A (en) * 1994-02-03 1999-08-10 The Picower Institute For Medical Research Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions

Also Published As

Publication number Publication date
EP0755249B1 (de) 2004-03-31
EP0755249A1 (de) 1997-01-29
JPH09512005A (ja) 1997-12-02
ES2216012T3 (es) 2004-10-16
DE69532804T2 (de) 2005-02-10
GB2288732B (en) 1998-04-29
PT755249E (pt) 2004-08-31
WO1995028151A1 (en) 1995-10-26
DE69532804D1 (de) 2004-05-06
ATE262895T1 (de) 2004-04-15
US5891873A (en) 1999-04-06
GB9407305D0 (en) 1994-06-08
GB2288732A (en) 1995-11-01
AU2219795A (en) 1995-11-10
US6034080A (en) 2000-03-07

Similar Documents

Publication Publication Date Title
DK0755249T3 (da) Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
NZ335981A (en) Ketobenzamides as calpain inhibitors
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
GB0005251D0 (en) Therapeutic compounds
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
ATE313326T1 (de) VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
NZ517616A (en) Use of retigabin for treating neuropathic pain
DK0705099T3 (da) Anvendelse af modafinil til behandling af søvnapnø og åndedrætslidelser af central oprindelse
DK0739212T3 (da) Anvendelse af interleukin-12 til forebyggelse af transplantat-vs.-værtssygdom
MXPA02002117A (es) Uso de productos leguminosos para el tratamiento de agresiones externas.
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
BG101138A (en) The use of glyceryltriacetate for the treatment of onychomycosis
MX9805290A (es) Utilizacion de inhibidores de la actividad del acido retinoico para tratar las pieles sensibles y/o los daños agudos inducidos por las radiaciones ultravioleta.
BR9612283A (pt) Composição para o tratamento de manchas em peças de roupa e métodos de tratamento
TR199900505T2 (de)
PL334498A1 (en) Application of pramiprexole in treating the restless legs syndrome
GB9916729D0 (en) Fuller for the treatment of leather,pelts and the like
ZA9711468B (en) New use of comt inhibitors
DE60235132D1 (de) Sojaprodukte enthaltende Zusammensetzungen
LV11593A (lv) Dimetikona pielietojums aizcietejumu arstesana
IL139144A0 (en) Mycobacterial inhibitors
DK1042288T3 (da) Tripeptidyl-peptidase inhibitorer
DE69906701D1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DE69716056D1 (de) Acylurea-verbindungen zur behandlung von coccidioidomycosis bei warmblütigen tieren
BR0012380A (pt) 2-amino-benzoxazinonas para o tratamento de vìrus do herpes simples